Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies

被引：69

作者：

Gore, M. E. ^{[1
]}

Larkin, J. M. G. ^{[1
]}

机构：

[1] Royal Marsden Hosp, Dept Med, London SW3 6JJ, England

来源：

BRITISH JOURNAL OF CANCER | 2011年 / 104卷 / 03期

关键词：

chronic disease; combinatorial therapy; renal cell carcinoma; sequential therapy; sunitinib malate; targeted agents; PHASE-II TRIAL; INTERFERON-ALPHA; 1ST-LINE TREATMENT; DOUBLE-BLIND; SUNITINIB; CANCER; SORAFENIB; TEMSIROLIMUS; BEVACIZUMAB; EVEROLIMUS;

D O I：

10.1038/sj.bjc.6606084

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Optimum efficacy is the primary goal for any cancer therapy, and entails controlling tumour growth and prolonging survival as far as possible. The prognosis for patients with metastatic renal cell carcinoma (mRCC) has greatly improved with the introduction of targeted therapies. This review examines the development and efficacy of targeted agents for the management of mRCC, the challenge; offered by their rapid emergence, and discusses how mRCC treatment may evolve in the future. Improvements in progression-free survival and overall survival rates, observed with targeted agents, indicate that it may now be possible to change mRCC from a rapidly fatal and largely untreatable condition into a chronic disease. The major challenges to further advances in targeted therapy for mRCC include overcoming drug resistance, identifying the most effective sequence or combination of targeted agents, optimising clinical trial design and managing the cost of treatment. British Journal of Cancer (2011) 104, 399 - 406. doi:10.1038/sj.bjc.6606084 www.bjcancer.com (C) 2011 Cancer Research UK

引用

页码：399 / 406

页数：8

共 58 条

[1] Challenges of antiangiogenic cancer therapy:: trials and errors, and renewed hope [J].

Angel Medina, Miguel ;

Munoz-Chapuli, Ramon ;

Quesada, Ana R. .

JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2007, 11 (03) :374-382

[2]

[Anonymous], 2010, J CLIN ONCOL

[3] The follow-up management of non-metastatic renal cell carcinoma: definition of a surveillance protocol [J].

Antonelli, Alessandro ;

Cozzoli, Alberto ;

Zani, Danilo ;

Zanotelli, Tiziano ;

Nicolai, Maria ;

Cunico, Sergio Cosciani ;

Simeone, Claudio .

BJU INTERNATIONAL, 2007, 99 (02) :296-300

[4]

Bhargava P, 2009, J CLIN ONCOL, V27

[5] Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma [J].

Bhojani, Naeem ;

Jeldres, Claudio ;

Patard, Jean-Jacques ;

Perrotte, Paul ;

Suardi, Nazareno ;

Hutterer, Georg ;

Patenaude, Francois ;

Oudard, Stephane ;

Karakiewicz, Pierre I. .

EUROPEAN UROLOGY, 2008, 53 (05) :917-930

[6] Effects of HIF-1 alpha and HIF2 alpha on Growth andMetabolism of Clear-Cell Renal Cell Carcinoma 786-0 Xenografts [J].

Biswas, Swethajit ;

Troy, Helen ;

Leek, Russell ;

Chung, Yuen-Li ;

Li, Ji-liang ;

Raval, Raju R. ;

Turley, Helen ;

Gatter, Kevin ;

Pezzella, Francesco ;

Griffiths, John R. ;

Stubbs, Marion ;

Harris, Adrian L. .

JOURNAL OF ONCOLOGY, 2010, 2010

[7] RETRACTED: Immunotherapy for advanced renal cell cancer - art. no. CD001425.pub2 (Retracted Article) [J].

Coppin, C ;

Porzsolt, F ;

Awa, A ;

Kumpf, J ;

Coldman, A ;

Wilt, T .

COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2005, (01)

[8]

DUTCHER JP, 2008, 44 ANN M AM SOC CLIN

[9]

EISEN T, 2009, EUR J CANC S7, V7

[10] Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].

Escudier, B. ;

Kataja, V. .

ANNALS OF ONCOLOGY, 2010, 21 :v137-v139

← 1 2 3 4 5 6 →